<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1665-5044</journal-id>
<journal-title><![CDATA[Revista mexicana de neurociencia]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. mex. neurocienc.]]></abbrev-journal-title>
<issn>1665-5044</issn>
<publisher>
<publisher-name><![CDATA[Academia Mexicana de Neurología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1665-50442023000300093</article-id>
<article-id pub-id-type="doi">10.24875/rmn.22000076</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Accelerate the diagnosis of amyotrophic lateral sclerosis using the Gold Coast criteria and biomarkers]]></article-title>
<article-title xml:lang="es"><![CDATA[Acelerar el diagnostico de esclerosis lateral amiotrófica utilizando los criterios Gold Coast y biomarcadores]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[Héctor R.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Tecnológico y de Estudios Superiores de Monterrey School of Medicine and Health Sciences ]]></institution>
<addr-line><![CDATA[San Pedro Garza García ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Zambrano Hellion Neurology and Neurosurgery Institute ]]></institution>
<addr-line><![CDATA[San Pedro Garza García ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2023</year>
</pub-date>
<volume>24</volume>
<numero>3</numero>
<fpage>93</fpage>
<lpage>98</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1665-50442023000300093&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1665-50442023000300093&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1665-50442023000300093&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Amyotrophic lateral sclerosis (ALS) is a chronic neurodegenerative disorder characterized by upper and lower motor neurons death, the diagnosis remains in clinical basis. Clinical criteria El Escorial for its diagnosis were published in 1994, the revised criteria in 2000 and modified by the Awaji criteria in 2008 to integrate electrophysiological data with the clinical examination. These criteria are complex to apply and have difficulties to determine progression through ALS categories. Recent advances in genetics, biomarkers such as light chain neurofilament (NfL), cytokines, neuroimaging, and neurophysiological probes of upper motor neuron dysfunction are not included in the diagnostic criteria. In 2019, new and simple ALS diagnostic criteria (Gold Coast criteria) have been introduced along with genetic testing and serum and cerebrospinal fluid NfL levels. Early diagnosis for initiating disease-modifying drugs and care in a multidisciplinary ALS clinic will improve quality of life and survival in ALS patients. In this article, I consider that it is an urgency to facilitate an early recognition of possible ALS among primary care physicians as well as to foster of urgency among neurologist to accelerate the diagnostic process of ALS to protect viable motor neurons and slow down the process of neurodegeneration.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen La esclerosis lateral amiotrófica (ELA) es un trastorno neurodegenerativo crónico caracterizado por la muerte selectiva de las neuronas motoras superiores (NMS) y neuronas motoras inferiores. El diagnóstico permanece en bases clínicas. Los criterios clínicos de El Escorial descritos en 1994, fueron revisados el año 2000 y modificados por criterios de Awaji en 2008 integrando datos clínicos y electrofisiológicos. Estos criterios son complejos para aplicarse, propensos a errores y difíciles de determinar evolución. Avances recientes en genética, biomarcadores como neurofilamento de cadena ligera (NfL), citocinas, neuroimagen y estudios neurofisiológicos no se incluyen en los criterios de diagnóstico actuales. En 2019, se introdujeron criterios nuevos y simples para el diagnóstico de ALS (criterios de Gold Coast) que incluyen imagen de resonancia magnética, biomarcadores en sangre y líquido cefalorraquídeo (NfL) y pruebas genéticas. El diagnóstico temprano para iniciar fármacos modificadores de la enfermedad y la atención en clínicas multidisciplinarias para ELA mejorarán calidad de vida y sobrevida de los pacientes. En este artículo, considero urgente facilitar el reconocimiento temprano de una posible ELA entre los médicos de atención primaria y neurólogos para acelerar el proceso diagnóstico de la ELA y tratar de proteger las neuronas motoras viables y desacelerar el proceso de neurodegeneración.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Amyotrophic lateral sclerosis]]></kwd>
<kwd lng="en"><![CDATA[Gold Coast criteria]]></kwd>
<kwd lng="en"><![CDATA[Biomarkers]]></kwd>
<kwd lng="en"><![CDATA[Riluzole]]></kwd>
<kwd lng="en"><![CDATA[Edaravone]]></kwd>
<kwd lng="en"><![CDATA[Relyvrio]]></kwd>
<kwd lng="es"><![CDATA[Esclerosis lateral amiotrofica]]></kwd>
<kwd lng="es"><![CDATA[Biomarcadores]]></kwd>
<kwd lng="es"><![CDATA[Riluzole]]></kwd>
<kwd lng="es"><![CDATA[Edavarona]]></kwd>
<kwd lng="es"><![CDATA[Relyvrio]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Swinnen]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Robberecht]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The phenotypic variability of amyotrophic lateral sclerosis]]></article-title>
<source><![CDATA[Nat Rev Neurol]]></source>
<year>2014</year>
<volume>10</volume>
<page-range>661-70</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mitsumoto]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kasarkis]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Simmons]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hastening the diagnosis of amyotrophic lateral sclerosis]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2022</year>
<volume>99</volume>
<page-range>60-8</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Przedborski]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Etiology and pathogenesis of Parkinson's disease]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Jankovic]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Tolosa]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Parkinson's Disease and Movement Disorders]]></source>
<year>2015</year>
<edition>6th ed</edition>
<page-range>51-64</page-range><publisher-loc><![CDATA[Philadelphia, PA, USA ]]></publisher-loc>
<publisher-name><![CDATA[Wolters Kluwer]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Foerster]]></surname>
<given-names><![CDATA[BR]]></given-names>
</name>
<name>
<surname><![CDATA[Welsh]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Feldman]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[25 Years of neuroimaging in amyotrophic lateral sclerosis]]></article-title>
<source><![CDATA[Nat Rev Neurol]]></source>
<year>2013</year>
<volume>9</volume>
<page-range>513-24</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martinez]]></surname>
<given-names><![CDATA[HR]]></given-names>
</name>
<name>
<surname><![CDATA[Molina-Lopez]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Cantú-Martinez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Gonzalez-Garza]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno-Cuevas]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Couret-Alcaraz]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Survival and clinical features in Hispanic amyotrophic lateral sclerosis patients]]></article-title>
<source><![CDATA[Amyotroph Lateral Scler]]></source>
<year>2011</year>
<volume>12</volume>
<page-range>199-205</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mehta]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Kaye]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Raymond]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Larson]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Punjani]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of amyotrophic lateral sclerosis United States, 2014]]></article-title>
<source><![CDATA[MMWR Morb Mortal Wkly Rep]]></source>
<year>2018</year>
<volume>67</volume>
<page-range>216-8</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mejzini]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Flynn]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
<name>
<surname><![CDATA[Pitout]]></surname>
<given-names><![CDATA[IL]]></given-names>
</name>
<name>
<surname><![CDATA[Fletcher]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Wilton]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Akkari]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ALS genetics, mechanisms, and therapeutics:where are we now?]]></article-title>
<source><![CDATA[Front Neurosci]]></source>
<year>2019</year>
<volume>13</volume>
<page-range>1310</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brooks]]></surname>
<given-names><![CDATA[BR]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
<name>
<surname><![CDATA[Swash]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Munsat]]></surname>
<given-names><![CDATA[TL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[World Federation of Neurology Research Group on Motor Neuron Disease El Escorial revisited:revised criteria for the diagnosis of amyotrophic lateral sclerosis]]></article-title>
<source><![CDATA[Amyotroph Lateral Scler Other Motor Neuron Disord]]></source>
<year>2000</year>
<volume>1</volume>
<page-range>293-9</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shefner]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Chalabi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Baker]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Cui]]></surname>
<given-names><![CDATA[LY]]></given-names>
</name>
<name>
<surname><![CDATA[de Carvalho]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Eisen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A new proposal for diagnostic criteria for ALS]]></article-title>
<source><![CDATA[Clin Neurophysiol]]></source>
<year>2020</year>
<volume>131</volume>
<page-range>1975-8</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zoccolella]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mstronardi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Scarafino]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Iliceto]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[D'Errico]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Fraddosio]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Motor-evoked potentials in amyotrophic lateral sclerosis:potential implications in detecting subclinical UMN involvement in lower motor neuron phenotype]]></article-title>
<source><![CDATA[J Neurol]]></source>
<year>2020</year>
<volume>267</volume>
<page-range>3689-95</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[HR]]></given-names>
</name>
<name>
<surname><![CDATA[Escamilla-Ocañas]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Tenorio-Pedraza]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Gomez-Almaguer]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Jaime-Perez]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Olguín-Ramírez]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cytokine network in amyotrophic lateral sclerosis:a pathway-based statistical analysis]]></article-title>
<source><![CDATA[Cytokine]]></source>
<year>2017</year>
<volume>90</volume>
<page-range>1-5</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Turner]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Progress and new frontiers in biomarkers for amyotrophic lateral sclerosis]]></article-title>
<source><![CDATA[Biomark Med]]></source>
<year>2018</year>
<volume>12</volume>
<page-range>693-6</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[HR]]></given-names>
</name>
<name>
<surname><![CDATA[Escamilla-Ocañas]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Gonzalez-Garza]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno-Cuevas]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical and magnetic resonance imaging abnormalities of the tongue in patients with amyotrophic lateral sclerosis]]></article-title>
<source><![CDATA[Neurología (Engl Ed)]]></source>
<year>2018</year>
<volume>4</volume>
<page-range>276-8</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roeben]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Wilke]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bender]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Ziemann]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Synofzik]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Motor band sign on MRI-SWI the motor band sign in ALS:presentations and frequencies in a consecutive series of ALS patients]]></article-title>
<source><![CDATA[J Neurol Sci]]></source>
<year>2019</year>
<volume>406</volume>
<page-range>116440</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[HR]]></given-names>
</name>
<name>
<surname><![CDATA[González-Garza]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno-Cuevas]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Caro-Osorio]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Gil-Valadez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ocañas]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Increase of pyramidal tract fractional anisotropy on MRI after stem cell transplantation in ALS patients]]></article-title>
<source><![CDATA[J Neurol Neurophysiol]]></source>
<year>2014</year>
<volume>5</volume>
<page-range>244</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martinez]]></surname>
<given-names><![CDATA[HR]]></given-names>
</name>
<name>
<surname><![CDATA[Figueroa-Sanchez]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Cantu-Martinez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Caraza]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[De la Maza]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Escamilla-Garza]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A multidisciplinary clinic for amyotrophic lateral sclerosis patients in Northeast Mexico]]></article-title>
<source><![CDATA[Rev Mex Neuroci]]></source>
<year>2020</year>
<volume>21</volume>
<page-range>66-708</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rooney]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Byrne]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Heverin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Tobin]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Dick]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Donaghy]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A multidisciplinary clinic approach improves survival in ALS:a comparative study of ALS in Ireland and Northern Ireland]]></article-title>
<source><![CDATA[J Neurol Neurosurg Psychiatry]]></source>
<year>2015</year>
<volume>86</volume>
<page-range>496-501</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="">
<collab>Riluzole</collab>
<source><![CDATA[Prescribing Information]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="">
<collab>Edaravone</collab>
<source><![CDATA[Prescribing Information]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="">
<collab>Relyvrio</collab>
<source><![CDATA[Prescribing Information]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Doble]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The pharmacology and mechanism of action of riluzole]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>1996</year>
<volume>47</volume>
<page-range>S233-41</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cheah]]></surname>
<given-names><![CDATA[BC]]></given-names>
</name>
<name>
<surname><![CDATA[Vucic]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Krishnan]]></surname>
<given-names><![CDATA[AV]]></given-names>
</name>
<name>
<surname><![CDATA[Kiernan]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Riluzole, neuroprotection and amyotrophic lateral sclerosis]]></article-title>
<source><![CDATA[Curr Med Chem]]></source>
<year>2010</year>
<volume>17</volume>
<page-range>1942-199</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Andrews]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Jackson]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Heiman-Patterson]]></surname>
<given-names><![CDATA[TD]]></given-names>
</name>
<name>
<surname><![CDATA[Bettica]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Brooks]]></surname>
<given-names><![CDATA[BR]]></given-names>
</name>
<name>
<surname><![CDATA[Pioro]]></surname>
<given-names><![CDATA[EP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis]]></article-title>
<source><![CDATA[Amyotroph Lateral Scler Frontotemporal Degener]]></source>
<year>2020</year>
<volume>21</volume>
<page-range>509-18</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abe]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Itoyama]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Sobue]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Tsuji]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Aoki]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Doyu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Confirmatory double-blind, parallel-group, placebo controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients]]></article-title>
<source><![CDATA[Amyotroph Lateral Scler Frontotemporal Degener]]></source>
<year>2014</year>
<volume>15</volume>
<page-range>610-7</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="book">
<collab>Radicava</collab>
<source><![CDATA[(Edaravone) Prescribing Information]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Jersey City, New Jersey ]]></publisher-loc>
<publisher-name><![CDATA[MT Pharma America, Inc]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Paganoni]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hendrix]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Dickson]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
<name>
<surname><![CDATA[Knowlton]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Macklin]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Berry]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis]]></article-title>
<source><![CDATA[Muscle Nerve]]></source>
<year>2021</year>
<volume>63</volume>
<page-range>31-9</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ryu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Camelo]]></surname>
<given-names><![CDATA[SI]]></given-names>
</name>
<name>
<surname><![CDATA[Carreras]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Iglesias]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice]]></article-title>
<source><![CDATA[J Neurochem]]></source>
<year>2005</year>
<volume>93</volume>
<page-range>1087-98</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Paganoni]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Macklin]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Hendrix]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Berry]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Elliot]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Maiser]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2020</year>
<volume>383</volume>
<page-range>919-30</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
